CoChat

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

Open access
Kohli, Anita, Osinusi, Anuoluwapo, Sims, Zayani, Nelson, Amy, Meissner, Eric G, Barrett, Lisa L, Bon, Dimitra, Marti, Miriam M, Silk, Rachel, Kotb, Colleen, Gross, Chloe, Jolley, Tim A, Sidharthan, Sreetha, Petersen, Tess, Townsend, Kerry, Egerson, D'Andrea, Kapoor, Rama, Spurlin, Emily, Sneller, Michael, Proschan, Michael, Herrmann, Eva, Kwan, Richard, Teferi, Gebeyehu, Talwani, Rohit, Diaz, Gabbie, Kleiner, David E, Wood, Brad J, Chavez, Jose, Abbott, Stephen, Symonds, William T, Subramanian, G Mani, Pang, Phillip S, McHutchison, John, Polis, Michael A, Fauci, Anthony S, Masur, Henry, Kottilil, Shyam · 2015 · The Lancet
Cited by 150

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background Direct acting anti-HCV drugs have demonstrated a high cure rate and favorable tolerability. The development of shorter courses of therapy may improve affordability and adherence. Sofosbuvir and ledipasvir together with ribavirin have yielded high efficacy when administered for 8, but not for 6 weeks. We hypothesized that addition of a third potent directly acting antiviral to sofosbuvir and ledipasvir would allow for shortened durations of therapy. Methods In this single center, open-label cohort, phase 2 atrial, sixty HCV GT-1 treatment naïve patients were sequentially enrolled onto three arms and treated with 12 weeks of sofosbuvir and ledipasvir (an NS5B nucleotide polymerase inhibitor and an NS5A inhibitor, respectively) (n=20); or 6 weeks with sofosbuvir, ledipasvir, and GS-9669 (a non-nucleoside NS5B inhibitor) (n=20) or 6 weeks with sofosbuvir, ledipasvir and GS-9451 (an NS3/4A protease inhibitor) (n=20). Patients and investigators were unmasked to treatment assignment. The primary efficacy analysis was SVR12 (HCV RNA less than the level of quantitation 12 weeks after treatment completion). Findings All subjects treated with sofosbuvir and ledipasvir for 12 weeks achieved SVR12 (95%CI: 83–100%). Nineteen of 20 patients (95% CI: 75–100%) treated with sofosbuvir, ledipasvir and GS-9669 achieved SVR12, with 1 patient relapsing 2 weeks after completion of therapy. Nineteen of 20 patients (95% CI: 75–100%) treated with sofosbuvir, ledipasvir, and GS-9451 for 6 weeks achieved SVR12, one patient was lost to follow up after achieving SVR4. There were no discontinuations of treatment due to adverse events. Interpretation In this small proof of concept study, two different three drug regimens administered for 6 weeks resulted in high cure rates for HCV infection with excellent tolerability. Funding NIAID, National Cancer Institute and Clinical Center Intramural Program. Clinical Trials.gov number NCT01805882. The study was also supported in part by the German Research Foundation (DFG) by the clinical research unit KFO 129 and a Collaborative Research and Development Agreement between NIH and Gilead Sciences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)61228-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 150

Metadata

Authors
Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E. G., Barrett, L. L., Bon, D., Marti, M. M., Silk, R., Kotb, C., Gross, C., Jolley, T. A., Sidharthan, S., Petersen, T., Townsend, K., Egerson, D., Kapoor, R., Spurlin, E., Sneller, M., Proschan, M., Herrmann, E., Kwan, R., Teferi, G., Talwani, R., Diaz, G., Kleiner, D. E., Wood, B. J., Chavez, J., Abbott, S., Symonds, W. T., Subramanian, G. M., Pang, P. S., McHutchison, J., Polis, M. A., Fauci, A. S., Masur, H., & Kottilil, S.
Venue
The Lancet
Publisher
Elsevier BV
Published
2015-03
Volume
385
Issue
9973
Pages
1107-1113
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2151063300
Cited by
150
References
1
FWCI
17.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. https://app.cochat.ai/papers/10.1016/s0140-6736(14)61228-9
The paper
Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E. G., Barrett, L. L., Bon, D., Marti, M. M., Silk, R., Kotb, C., Gross, C., Jolley, T. A., Sidharthan, S., Petersen, T., Townsend, K., Egerson, D., Kapoor, R., Spurlin, E., Sneller, M., . . . Kottilil, S. (2015). Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. The Lancet. https://doi.org/10.1016/s0140-6736(14)61228-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.